Unlocking Strategic Value:
The Competitive Advantage of
Publishing Real-World Evidence
Beyond Clinical Trials
Unlocking Strategic Value:
The Competitive Advantage of Publishing Real-World Evidence Beyond Clinical Trials
Authors: Dr. Bhavna Tyagi, Utsavi, Saloni Agarwal I
Clinical Affairs, Remedium Consultancy
The pharmaceutical industry is at a critical inflection point. With the cost of bringing a new drug to market now exceeding $2 billion, the return on investment (ROI) has plummeted by an estimated 62%. This economic imbalance is exerting unprecedented pressure across the drug development ecosystem. Despite promising outcomes in early-phase trials, late-stage attrition is rising, driven by tightening regulatory expectations, increasing trial complexity, and the mounting costs of precision medicine.
In response, pharmaceutical companies are re-evaluating traditional models and seeking strategies to extend value across the development lifecycle. A key yet underleveraged opportunity lies in the strategic publication of real-world data. Far from being a procedural formality, the publication of real-world data plays a pivotal role in clinical decision-making, evidence generation, and stakeholder engagement. Real-world evidence bridges the gap between the tightly controlled conditions of randomized clinical trials (RCTs) and the complexities of routine clinical practice, offering a pragmatic and impactful pathway forward.
Powered by Real-World Sources,
Real-World Data Delivers Deeper Clinical Insight
Real-world data captures the diversity and complexity of everyday clinical care. Real-world data reflects real treatment patterns, patient variability, and long-term outcomes. Sourced from electronic health records (EHRs), insurance claims, registries, and patient-reported outcomes, Real-world data is both expansive and dynamic, making it a valuable complement to traditional clinical evidence.
Figure1: Source of Real-World Data
When appropriately analysed and published, real-world data offers multidimensional insights that support decision-making across regulatory, clinical, and commercial domains.
Powered by Real-World Sources, Real-World Data Delivers Deeper Clinical Insight
Real-world data captures the diversity and complexity of everyday clinical care. Real-world data reflects real treatment patterns, patient variability, and long-term outcomes. Sourced from electronic health records (EHRs), insurance claims, registries, and patient-reported outcomes, Real-world data is both expansive and dynamic, making it a valuable complement to traditional clinical evidence.
Figure1: Source of Real-World Data
When appropriately analysed and published, real-world data offers multidimensional insights that support decision-making across regulatory, clinical, and commercial domains.
Medical Affairs teams are increasingly leveraging
diverse publication formats to deepen engagement and
extend the scientific narrative beyond the confines of trials:
Figure 3: Real-World Data to diverse publication formats to deepen engagement and extend the scientific narrative
The Strategic Role of
Real-World Data in Medical Affairs
Medical Affairs is uniquely positioned at the intersection of clinical science, stakeholder engagement, and evidence generation. Real-World Data empowers Medical Affairs teams to augment clinical trial data with evidence reflective of routine practice, enhancing the real-world relevance of scientific communications.
For instance, pragmatic trials-designed to evaluate treatment effectiveness in real-world settings-illustrate how real-world data complements traditional methodologies. Transparent dissemination of such findings enhances trust among regulators, clinicians, and payers, establishing Medical Affairs as a key driver of scientific credibility and strategy.
Best Practices for Transparent Real-World Evidence Studies
Advantages of Real-World Data Beyond Clinical Trials
Real-World Data offers strategic advantages that extend well beyond evidentiary support:
Future Research and Innovation
Real-World Data is not only shaping current practices but also driving the future of drug development. Regulatory bodies like the FDA are actively integrating real-world evidence into their decision frameworks. A landmark example occurred in 2021 when the U.S Food and Drug Administration (FDA) approved a new indication for tacrolimus (Prograf) based on real-world registry data-a non-interventional study that demonstrated improved outcomes in lung transplant recipients.
This milestone underscores the growing regulatory acceptance of real-world evidence and highlights its potential to:
- Refine trial design and eligibility criteria
- Accelerate label expansions
- Inform post-marketing commitments and lifecycle management
Final Thoughts
Medical Affairs serves as the custodian of scientific integrity, clinical insight, and strategic evidence generation. The timely and strategic publication of real-world data enhances clinical relevance, accelerates access, and strengthens
stakeholder trust.
At Remedium, our Medical Affairs team is equipped to unlocking the full potential of real-world data. We specialize in transforming intricate clinical insights into clear and compelling publications that resonate with healthcare professionals
and stakeholders alike. Leveraging deep therapeutic expertise and rigorous scientific standards, we deliver high-impact evidence that drives informed decision-making
Now is the time to integrate real-world data into your evidence generation strategy to drive meaningful impact well beyond the boundaries of clinical trials.
References
- Dagenais S, Russo L, Madsen A, Webster J, Becnel L. Use of Real-World Evidence to Drive Drug Development Strategy and Inform Clinical Trial Design. Clin Pharmacol Ther. 2022;111(1):77-89. doi:10.1002/cpt.2480
- Liu F, Panagiotakos D. Real-world data: a brief review of the methods, applications, challenges and opportunities. BMC Med Res Methodol. 2022;22:287. https://doi.org/10.1186/s12874-022-01768-6
